June 19, 2015Open Access

Effect of JAK Inhibitors on Release of CXCL9, CXCL10 and CXCL11 from Human Airway Epithelial Cells

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

These data suggest that the novel JAK inhibitor, PF1367550, is more potent than PF956980 and that JAK pathway inhibition in airway epithelium could provide an alternative anti-inflammatory approach for glucocorticosteroid-resistant diseases including COPD.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Fenwick et al. (Fri,) studied this question.

synapsesocial.com/papers/69dc5c3f3080d3567e274fad https://doi.org/https://doi.org/10.1371/journal.pone.0128757

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1NEUTROPHILS FROM SUBJECTS WITH CHRONIC OBSTRUCTIVE LUNG DISEASE SHOW ENHANCED CHEMOTAXIS AND EXTRACELLULAR PROTEOLYSIS1987 · 175 citations
2Tofacitinib2013 · 80 citations
3International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study2007 · 2,381 citations
4PROSPECTIVE RANDOMISED TRIAL OF METRONIDAZOLE VERSUS VANCOMYCIN FOR CLOSTRIDIUM-DIFFICILE-ASSOCIATED DIARRHOEA AND COLITIS1983 · 788 citations
5CD8 + ve Cells in the Lungs of Smokers with Chronic Obstructive Pulmonary Disease1999 · 485 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo